204 related articles for article (PubMed ID: 31937922)
41. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer.
Wang C; Mu Z; Chervoneva I; Austin L; Ye Z; Rossi G; Palazzo JP; Sun C; Abu-Khalaf M; Myers RE; Zhu Z; Ba Y; Li B; Hou L; Cristofanilli M; Yang H
Breast Cancer Res Treat; 2017 Jan; 161(1):83-94. PubMed ID: 27771841
[TBL] [Abstract][Full Text] [Related]
42. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.
Goldkorn A; Ely B; Quinn DI; Tangen CM; Fink LM; Xu T; Twardowski P; Van Veldhuizen PJ; Agarwal N; Carducci MA; Monk JP; Datar RH; Garzotto M; Mack PC; Lara P; Higano CS; Hussain M; Thompson IM; Cote RJ; Vogelzang NJ
J Clin Oncol; 2014 Apr; 32(11):1136-42. PubMed ID: 24616308
[TBL] [Abstract][Full Text] [Related]
43. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
Cohen SJ; Punt CJ; Iannotti N; Saidman BH; Sabbath KD; Gabrail NY; Picus J; Morse M; Mitchell E; Miller MC; Doyle GV; Tissing H; Terstappen LW; Meropol NJ
J Clin Oncol; 2008 Jul; 26(19):3213-21. PubMed ID: 18591556
[TBL] [Abstract][Full Text] [Related]
44. Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch® System and the AdnaTest®.
Gorges TM; Stein A; Quidde J; Hauch S; Röck K; Riethdorf S; Joosse SA; Pantel K
PLoS One; 2016; 11(5):e0155126. PubMed ID: 27182774
[TBL] [Abstract][Full Text] [Related]
45. Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools.
Gerratana L; Davis AA; Polano M; Zhang Q; Shah AN; Lin C; Basile D; Toffoli G; Wehbe F; Puglisi F; Behdad A; Platanias LC; Gradishar WJ; Cristofanilli M
Eur J Cancer; 2021 Jan; 143():147-157. PubMed ID: 33307492
[TBL] [Abstract][Full Text] [Related]
46. Circulating tumour cells and lung microvascular tumour cell retention in patients with metastatic breast and cervical cancer.
Peeters DJ; Brouwer A; Van den Eynden GG; Rutten A; Onstenk W; Sieuwerts AM; Van Laere SJ; Huget P; Pauwels P; Peeters M; Vermeulen PB; Dirix LY
Cancer Lett; 2015 Jan; 356(2 Pt B):872-9. PubMed ID: 25449778
[TBL] [Abstract][Full Text] [Related]
47. Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker.
Liu Y; Liu Q; Wang T; Bian L; Zhang S; Hu H; Li S; Hu Z; Wu S; Liu B; Jiang Z
BMC Cancer; 2013 Apr; 13():202. PubMed ID: 23617715
[TBL] [Abstract][Full Text] [Related]
48. Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer.
Shishido SN; Carlsson A; Nieva J; Bethel K; Hicks JB; Bazhenova L; Kuhn P
J Transl Med; 2019 Aug; 17(1):294. PubMed ID: 31462312
[TBL] [Abstract][Full Text] [Related]
49. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
[TBL] [Abstract][Full Text] [Related]
50. Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer.
Deutsch TM; Riethdorf S; Nees J; Hartkopf AD; Schönfisch B; Domschke C; Sprick MR; Schütz F; Brucker SY; Stefanovic S; Sohn C; Pantel K; Trumpp A; Schneeweiss A; Wallwiener M
Breast Cancer Res Treat; 2016 Nov; 160(2):277-290. PubMed ID: 27696083
[TBL] [Abstract][Full Text] [Related]
51. Assessment of the Clinical Utility of Circulating Tumor Cells at Different Time Points in Predicting Prognosis of Patients With Small Cell Lung Cancer: A Meta-Analysis.
Jiang AM; Zheng HR; Liu N; Zhao R; Ma YY; Bai SH; Tian T; Liang X; Ruan ZP; Fu X; Yao Y
Cancer Control; 2021; 28():10732748211050581. PubMed ID: 34654345
[TBL] [Abstract][Full Text] [Related]
52. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?
Dawood S; Broglio K; Valero V; Reuben J; Handy B; Islam R; Jackson S; Hortobagyi GN; Fritsche H; Cristofanilli M
Cancer; 2008 Nov; 113(9):2422-30. PubMed ID: 18785255
[TBL] [Abstract][Full Text] [Related]
53. The clinical value of circulating tumour cells (CTCs) in patients undergoing pulmonary metastasectomy for metastatic colorectal cancer.
Hashimoto M; Tanaka F; Yoneda K; Takuwa T; Kuroda A; Matsumoto S; Okumura Y; Kondo N; Tsujimura T; Nakano T; Hasegawa S
J Thorac Dis; 2018 Mar; 10(3):1569-1577. PubMed ID: 29707308
[TBL] [Abstract][Full Text] [Related]
54. Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study.
Müller V; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer E; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T;
Breast Cancer Res; 2012 Aug; 14(4):R118. PubMed ID: 22894854
[TBL] [Abstract][Full Text] [Related]
55. RNA Profiles of Circulating Tumor Cells and Extracellular Vesicles for Therapy Stratification of Metastatic Breast Cancer Patients.
Keup C; Mach P; Aktas B; Tewes M; Kolberg HC; Hauch S; Sprenger-Haussels M; Kimmig R; Kasimir-Bauer S
Clin Chem; 2018 Jul; 64(7):1054-1062. PubMed ID: 29769179
[TBL] [Abstract][Full Text] [Related]
56. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
[TBL] [Abstract][Full Text] [Related]
57. Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells.
Mout L; van Dessel LF; Kraan J; de Jong AC; Neves RPL; Erkens-Schulze S; Beaufort CM; Sieuwerts AM; van Riet J; Woo TLC; de Wit R; Sleijfer S; Hamberg P; Sandberg Y; Te Boekhorst PAW; van de Werken HJG; Martens JWM; Stoecklein NH; van Weerden WM; Lolkema MP
Eur J Cancer; 2021 Jun; 150():179-189. PubMed ID: 33932725
[TBL] [Abstract][Full Text] [Related]
58. Detection of circulating tumor cells in different stages of prostate cancer.
Thalgott M; Rack B; Maurer T; Souvatzoglou M; Eiber M; Kreß V; Heck MM; Andergassen U; Nawroth R; Gschwend JE; Retz M
J Cancer Res Clin Oncol; 2013 May; 139(5):755-63. PubMed ID: 23358719
[TBL] [Abstract][Full Text] [Related]
59. Gene Expression Analysis of Immunomagnetically Enriched Circulating Tumor Cell Fraction in Castration-Resistant Prostate Cancer.
Škereňová M; Mikulová V; Čapoun O; Švec D; Kološtová K; Soukup V; Honová H; Hanuš T; Zima T
Mol Diagn Ther; 2018 Jun; 22(3):381-390. PubMed ID: 29725990
[TBL] [Abstract][Full Text] [Related]
60. Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial.
Basso U; Facchinetti A; Rossi E; Maruzzo M; Conteduca V; Aieta M; Massari F; Fraccon AP; Mucciarini C; Sava T; Santoni M; Pegoraro C; Durante E; Nicodemo M; Perin A; Bearz A; Gatti C; Fiduccia P; Diminutto A; Barile C; De Giorgi U; Zamarchi R; Zagonel V
Oncologist; 2021 Sep; 26(9):740-750. PubMed ID: 34077597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
